Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1282-1287

  Castle, Jessica R ^a   Engle, Julia M ^b   El Youssef, Joseph ^a   Massoud, Ryan G ^b   Yuen, Kevin C J ^a   Kagan, Ryland ^b   Ward, W Kenneth ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCAGON; GLUCOSE; INSULIN ASPART; PLACEBO; HORMONE;

ADULT; ARTICLE; AUTOMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INFUSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; NAUSEA AND VOMITING; SINGLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; HORMONES; HUMANS; HYPOGLYCEMIA; MALE; TREATMENT OUTCOME;

EID: 77956071742     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2254     Document Type: Article

References (21)

1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-1912
2. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-948
3. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-3350 (Pubitemid 44923591)
4. El Youssef JE, Castle J, Ward WK. A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Algorithms 2009;2:518-532
5. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers J Pharm Sci 1999;88:991-995
6. Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006;42:108-111
7. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001;24:643-645 (Pubitemid 32888841)
8. Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H. Wearable artificial endocrine pancrease with needle-type glucose sensor. Lancet 1982;2:1129-1131
9. Ward WK, Engle J, Duman HM, Bergstrom CP, Sonia FK, Federiuk IF. The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors J 2008;8:89-96
10. El-Khatib FH, Jiang J, Damiano ER. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic Swine. J Diabetes Sci Technol 2007;1:181-192
11. Gopakumaran B, Duman HM, Overholser DP, Federiuk IF, Quinn MJ, Wood MD, Ward WK. A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method. Artif Organs 2005;29:599-607
12. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469-476 (Pubitemid 41532446)
13. Food and Agriculture Organization. Carbohydrates in human nutrition, Food and Agriculture Organization [article online], 1998. Available from http://www.fao.org/docrep/w8079e/w8079e0a.htm. Accessed 15 April 2010
14. Clinical and Laboratory Standards Institute. Performance metrics for continuous interstitial glucose monitoring: approved guideline, Clinical and Laboratory Standards Institute [article online], 2008. Available from http://www.clsi.org/source/orders/free/poct05-A.pdf. Accessed 15 April 2010
15. Bolli G, De Feo P, Perriello G, De Cosmo S, Compagnucci P, Santeusanio F, Brunetti P, Unger RH. Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man: role of the beta cell and arterial hyperinsulinemia J Clin Invest 1984;73:917-922
16. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol 2006;355:501-523
17. De Jong KL, Incledon B, Yip CM, DeFelippis MR. Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. Biophys J 2006;91:1905-1914
18. El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo. Diabetes Technol Ther 2007;9:135-144 (Pubitemid 46652547)
19. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res 2004;21:1274-1283
20. Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F. Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007;63:599-601
21. Matilainen L, Maunu SL, Pajander J, Auriola S, Jaaskelainen I, Larsen KL, Jarvinen T, Jarho P. The stability and dissolution properties of solid glucagon/gamma-cyclodextrin powder. Eur J Pharmacol Sci 2009;36:412-420